Navigation Links
AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
Date:12/7/2009

Response Rate Increases to 41% and Median Overall Survival Reported at 25

Months for All Evaluable Patients

QUEBEC CITY, Dec. 7 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that its partner Keryx Biopharmaceuticals Inc. ("Keryx") ( KERX) reported updated efficacy and safety data as well as new survival data on the clinical activity of perifosine (KRX-0401) in combination with bortezomib (Velcade(R)) (+/- dexamethasone) in patients with relapsed/refractory multiple myeloma. Data from the study entitled "A Multicenter Phase 1/2 Study Evaluating the Safety and Efficacy of Perifosine (KRX-0401) + Bortezomib (Velcade(R)) in Patients with Relapsed or Relapsed / Refractory Multiple Myeloma Who Were Previously Treated with Bortezomib," was presented on Saturday, December 5th at the 51st annual meeting of the American Society of Hematology, in a poster presentation by Dr. Paul Richardson, Clinical Director of the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute. Keryx is AEterna Zentaris' partner and licensee for perifosine in the United States, Canada and Mexico. Perifosine is also out-licensed to Handok in South Korea while AEterna Zentaris retains rights for the rest of the world.

Trial Results

Eighty-four patients with relapsed/refractory multiple myeloma were enrolled in a combined Phase 1/2 study (18 patients in the Phase 1 component and 66 patients in the Phase 2 component). The patients enrolled were heavily pre-treated with a median of 5 prior lines of therapy (range 1 - 13), including:

    - 100% of patients had been treated with bortezomib (55% of the patients
      were previously treated with at least two bortezomib-based therap
'/>"/>
SOURCE  AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013 Vital Imaging ... University of California, San Diego for a joint study ... Gravitic™ MRI (Magnetic Resonance Imaging) with that of a ... its continued pursuit of improved healthcare by combining cutting ... is an extremely valuable tool for evaluating pathological changes ...
(Date:5/21/2013)... CA (PRWEB) May 21, 2013 Clinovo's ... is an 8-week training program starting on June 11th, ... help clinical trial professionals reach the next step in ... Dentons Offices in Palo Alto, and streamed online. , ... of award-winning papers, Clinovo's new “CDISC Standards: Theory and ...
(Date:5/20/2013)... 20, 2013 Today, at the American Psychiatric ... , James McGough , M.D., M.S., ... Semel Institute for Neuroscience and Human Behavior and ... the University of California Los Angeles (UCLA), and director ... Psychopharmacology and ADHD at UCLA, presented the results of ...
(Date:5/20/2013)... ROCKVILLE , Md. and BALTIMORE ... Inc. (BHI), a regional private-public partnership focusing ... to early-stage funding in Central Maryland ... Aiyar, Ph.D., M.B.A., as the first Entrepreneur-in-Residence (EIR) ... (NIH) National Heart, Lung and Blood Institute ...
Breaking Biology Technology:Vital Imaging Makes Greater Commitment into MRI Research 2Vital Imaging Makes Greater Commitment into MRI Research 3Clinovo Launches TechTrainings on CDISC Standards 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 3Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 4Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 5BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 2BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 3BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 4
... - iCo Therapeutics Inc. (TSX-V: ICO) is pleased to ... This financing provides the company with sufficient capital to ... 1 clinical trial. iCo-007 is targeting the treatment of ... the company with additional working capital. iCo,s partner Isis ...
... Inc. (Nasdaq: VRUS ), a clinical ... commercializing novel drugs to treat viral infections, reported ... quarter ended December 31, 2008. Financial Results ... quarters ended December 31, 2008 and December 31, ...
... 9 Celsis In Vitro Technologies (Celsis,IVT), a ... science,products and laboratory services company, and Wisconsin-based Promega ... ADME-Tox testing in primary,hepatocytes. Celsis IVT is ... with Promega,s bioluminescent ADME-Tox assays, including,the P450-Glo(TM) CYP ...
Cached Biology Technology:iCo Therapeutics Closes $1.3 Million Private Placement 2iCo Therapeutics Closes $1.3 Million Private Placement 3Pharmasset Reports Fiscal First Quarter 2009 Financial Results 2Pharmasset Reports Fiscal First Quarter 2009 Financial Results 3Pharmasset Reports Fiscal First Quarter 2009 Financial Results 4Pharmasset Reports Fiscal First Quarter 2009 Financial Results 5Pharmasset Reports Fiscal First Quarter 2009 Financial Results 6Pharmasset Reports Fiscal First Quarter 2009 Financial Results 7Pharmasset Reports Fiscal First Quarter 2009 Financial Results 8Celsis In Vitro Technologies and Promega to Offer Fast, Reliable Solutions for ADME-Tox Testing With Primary Hepatocytes 2Celsis In Vitro Technologies and Promega to Offer Fast, Reliable Solutions for ADME-Tox Testing With Primary Hepatocytes 3
(Date:5/21/2013)... of Michigan Water Center today awarded 12 research ... restoration and protection efforts. , The two-year grants ... including efforts to track the remediation of harmful ... control non-native weedy plant invasions; study chromosomal damage ... to restoration activities. , The grants were awarded ...
(Date:5/21/2013)... the past few decades, scientists have developed many devices ... metallic stents. While generally effective, each of these treatments ... A new study from MIT analyzes the potential usefulness ... angioplasty balloons and drug-releasing stents, but may pose fewer ... in the artery for only a brief period, during ...
(Date:5/20/2013)... are also commonly resistant to antimicrobial substances made ... in mBio , the online open-access journal ... colistin and host antimicrobials LL-37 and lysozyme, which ... mean that patients with life-threatening multi-drug resistant infections ... Colistin is a last-line drug for treating several ...
Breaking Biology News(10 mins):U-M Water Center awards $570K in Great Lakes restoration grants 2U-M Water Center awards $570K in Great Lakes restoration grants 3U-M Water Center awards $570K in Great Lakes restoration grants 4Evaluating a new way to open clogged arteries 2Evaluating a new way to open clogged arteries 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
... 2011Mary Ann Liebert, Inc., publishers ( http://www.liebertpub.com ) ... Technology , a highly innovative, bimonthly peer-reviewed journal ... the potential to significantly improve human health, well-being, ... innovative results, essential data, cutting-edge discoveries, thorough syntheses ...
... November 14, 2011 The possibility that functional, three-dimensional ... such as embryonic stem cells (ESCs) and induced pluripotent ... of stem cell research, but is also one of ... medicine. Developmental biology has played a central role in ...
... University Hospitals Case Medical Center researchers could still be ... not as they originally thought. LateTIME was a ... marrow that were believed to have the ability to ... the heart within two weeks of the attack. Results ...
Cached Biology News:New journal on disruptive science and technology launching in 2012 2Self-organized pituitary-like tissue from mouse ES cells 2Self-organized pituitary-like tissue from mouse ES cells 3Self-organized pituitary-like tissue from mouse ES cells 4Post heart attack recovery may not be aided by stem cell injections, but trial demonstrates promise 2
... for easy storage. Linkage: This CLS number is ... Cornings product number. If showing no availability yet, ... or contact customer service for assistance. ID clarifier: ... 55 cm 2 D H 100 ...
... Mixes are formulated for use in one-step ... Green. One-step QRT-PCR mixes offer a quick ... pipetting steps are minimised, making the protocol ... 2x ABsolute QRT-PCR Mix is supplied with ...
... wide variety of environmental and pathophysiological stressful ... of proteins known as heat shock proteins ... proteins (SRPs). The Hsp90 family of ... alpha and beta, Grp94, and Trap-1 (Hsp75). ...
... offers bespoke, cost-effective solutions for complex protein processing and ... and experience to help you develop a solution to ... , ... transfer all methodology to your ...
Biology Products: